Blood test triggers early immunotherapy in bladder cancer trial
NCT ID NCT04138628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether starting immunotherapy earlier—based on a blood test that finds tumor DNA—can control bladder cancer that may have spread after the bladder is removed. About 154 adults whose cancer has returned or is at high risk of spreading will receive the treatment. The goal is to see if this approach leads to better outcomes than waiting for tumors to show up on scans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aalborg Universitetshospital
Aalborg, 9100, Denmark
-
Aarhus University Hospital
Aarhus, 8200, Denmark
-
Herlev Hospital
Herlev, 2730, Denmark
-
Odense Universitetshospital
Odense, 5000, Denmark
-
Rigshospitalet
Copenhagen, 2100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bag-Like device pull bladder tumors out whole?
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Bladder cancer: a new combo aims to avoid radical surgery
- Can a special PET scan see bladder cancer more clearly?
- Could a simple urine test spare bladder cancer patients from chemotherapy?
- Can a new drug rally the immune system against Hard-to-Treat cancers?